BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases

Florina Grigore, Hana Yang, Nicholas D. Hanson, Matthew W. VanBrocklin, Aaron L. Sarver, James P. Robinson

Research output: Contribution to journalArticlepeer-review

Abstract

The development of mutant BRAF inhibitors has improved the outcome for melanoma patients with BRAFV600E mutations. Although the initial response to these inhibitors can be dramatic, sometimes resulting in complete tumor regression, the majority of melanomas become resistant. To study resistance to BRAF inhibition, we developed a novel mouse model of melanoma using a tetracycline/doxycycline-regulated system that permits control of mutant BRAF expression. Treatment with doxycycline leads to loss of mutant BRAF expression and tumor regression, but tumors recur after a prolonged period of response to treatment. Vemurafenib, encorafenib and dabrafenib induce cell cycle arrest and apoptosis in BRAF melanoma cell lines; however, a residual population of tumor cells survive. Comparing gene expression in human cell lines and mouse tumors can assist with the identification of novel mechanisms of resistance. Accordingly, we conducted RNA sequencing analysis and immunoblotting on untreated and doxycycline-treated dormant mouse melanomas and human mutant BRAF melanoma cell lines treated with 2 μM vemurafenib for 20 days. We found conserved expression changes in histone methyltransferase genes ASH2, EZH2, PRMT5, SUV39H1, SUV39H2, and SYMD2 in P-ERK low, p-38 high melanoma cells following prolonged BRAF inhibition. Quantitative mass spectrometry, determined a corresponding reduction in histone Lys9 and Lys27 methylation and increase in Lys36 methylation in melanoma cell lines treated with 2 μM vemurafenib for 20 days. Thus, these changes as are part of the initiate response to BRAF inhibition and likely contribute to the survival of melanoma cells.

Original languageEnglish (US)
Pages (from-to)376-389
Number of pages14
JournalNeoplasia (United States)
Volume22
Issue number9
DOIs
StatePublished - Sep 2020

Bibliographical note

Funding Information:
This work was supported by a Research Scholar Grant ‘Defining resistance to BRAF inhibition in melanoma’ RSG-17-230-01-TBG from the American Cancer Society .

Keywords

  • BRAF
  • Histone
  • Melanoma
  • Mouse
  • Resistance

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases'. Together they form a unique fingerprint.

Cite this